Brief: Apexigen To Reduce Workforce, Exploring Sale
27/02/2023 13:53
Feb 27 (Reuters) - Apexigen Inc APGN.O :
* APEXIGEN ANNOUNCES REVIEW OF STRATEGIC ALTERNATIVES AND
RESTRUCTURING
* CO WILL EXPLORE POTENTIAL FOR AN ACQUISITION, COMPANY
SALE,
MERGER, DIVESTITURE OF ASSETS, LICENSING, OR OTHER STRATEGIC
TRANSACTIONS
* PLANS TO REDUCE ITS WORKFORCE BY 55%
* CO WILL ALSO IMPLEMENT A CORPORATE RESTRUCTURING TO EXTEND
ITS
CASH RUNWAY AS IT REVIEWS AND EXPLORES STRATEGIC ALTERNATIVES
Source text for Eikon: ID:nGNX8yb0kR
Further company coverage: APGN.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Apexigen
See all newsBrief: Apexigen Inc - On August 15, Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard Transfer Of Listing From Nasdaq
Brief: Apexigen Says Phase 2 Data Evaluating Sotigalimab, Its CD40 Agonist Antibody, In Combination With Doxorubicin Marked Increases In Overall Survival Observed Across Soft Tissue Sarcoma Patients
Apexigen rises on buyout deal with Pyxis Oncology
Brief: Pyxis Oncology To Acquire Apexigen For Total Enterprise Value Of About $16 Million
Brief: Apexigen Inc Says On April 11, Co Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard From Nasdaq